Full Description
With the new classification of chronic myeloproliferative disorders, and the rise of interest in molecularly targeted therapies, this timely text brings together international experts on the topic to discuss the current technologies and their implications for the treatment of patients.
This title comprehensively covers chronic myeloid leukemia and Ph-negative chronic myeloproliferative disorders and is an essential resource for all practitioners in Hematologic Oncology.
Contents
I. Bcr/Abl Positive Chronic Myeloproliferative Disorders. 1. Epidemiology and history. 2. Cytogenetics and molecular biology. 3. Risk stratification. 4. Clinical features. 5. Non-transplant treatment options. 6. Allogeneic stem cell transplantation. 7. Autologous stem cell transplantation. 8. Vaccines. 9. A therapeutic algorithm and concluding remarks. II. Bcr/Abl Negative Chronic Myeloproliferative Disorders. 10. Epidemiology and history. 11. Cytogenetics and molecular biology. 12. Risk stratification. 13. Clinical features. 14. Non-transplant treatment options. 15. Transplantation options. 16. A therapeutic algorithm and concluding remarks.
